The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2017-04-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14656566.2017.1317748PMID 28426260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease

  2017cited by this paper
• Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

  2017cited by this paper
• Standards of Medical Care in Diabetes-2017: Summary of Revisions.

  2017cited by this paper
• Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway.

  2016cited by this paper
• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

  2016cited by this paper
• Standards of Medical Care in Diabetes—2017: Summary of Revisions

  2016cited by this paper
• Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area.

  2016cited by this paper
• Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

  2016cited by this paper
• The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

  2016cited by this paper
• Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

  2016cited by this paper
• Reference Values and Age Differences in Body Composition of Community-Dwelling Older Japanese Men and Women: A Pooled Analysis of Four Cohort Studies

  2015cited by this paper
• Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy

  2015cited by this paper
• Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.

  2014cited by this paper
• Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

  2014cited by this paper
• BMI Cut Points to Identify At-Risk Asian Americans for Type 2 Diabetes Screening

  2014cited by this paper
• Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

  2014cited by this paper
• Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise

  2014cited by this paper
• Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

  2013cited by this paper
• Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

  2013cited by this paper
• KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

  2012cited by this paper
• By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012.

  2012cited by this paper
• Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

  2012cited by this paper
• IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

  2011cited by this paper
• InBody 720 as a new method of evaluating visceral obesity.

  2011cited by this paper
• Adiposopathy is "sick fat" a cardiovascular disease?

  2011cited by this paper
• Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes.

  2011cited by this paper
• IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

  2011cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010cited by this paper
• The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

  2010cited by this paper
• Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

  2010cited by this paper
• Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

  2010cited by this paper
• Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.

  2009cited by this paper
• Metabolic Syndrome Pandemic

  2008cited by this paper
• How strong is the association between abdominal obesity and the incidence of type 2 diabetes?

  2008cited by this paper
• Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

  2007cited by this paper
• A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance.

  2005cited by this paper

• The Efficacy of Pharmacotherapy in the Treatment of Obesity in Patients With Type 2 Diabetes: A Systematic Review

  2024influential citation
• Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis

  2024influential citation
• Comparison of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinediones for Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

  2023cites this paper
• New advances in the application of sodium-glucose cotransporter-2 inhibitors in multisystem diseases

  2023cites this paper
• The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review

  2023cites this paper
• Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors.

  2023cites this paper
• Analysing uric acid levels to assess the effectiveness of dapagliflozin.

  2023cites this paper
• The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors

  2022influential citation
• Different Indicators of Adiposity and Fat Distribution and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes

  2021cites this paper
• Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta‐analysis

  2021cites this paper
• Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials

  2020cites this paper
• An overview of prospective drugs for type 1 and type 2 diabetes.

  2019cites this paper
• Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study.

  2018cites this paper
• Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial

  2018cites this paper
• Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial

  2018cites this paper